相关实验视频

Updated: Jun 19, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

评估VLA-4 (Integrin α4β1) 作为固体瘤中放射性药物治疗的共同目标

Jeyshka M Reyes-González¹, Harikrishnan Rajkumar², Woonghee Lee³

¹National Cancer Institute, Bethesda, United States.

Molecular cancer therapeutics

|February 6, 2025

概括

血管细胞粘附分子1 (VLA-4) 是固体瘤放射性药物治疗 (RPT) 的一个有前途的目标. 临床前研究表明[67Cu]Cu-LLP2A耐受性良好且有效,需要进一步研究.

科学领域:

在瘤学瘤学.
放射性药物疗法是一种放射性药物疗法.
分子成像学分子成像学

背景情况:

放射性药物治疗 (RPT) 面临着挑战,因为固体瘤缺乏广泛表达的标.
血管细胞粘附分子1 (VLA-4),也称为整合素α4β1,作为潜在的泛癌标被探索.
编码VLA-4α4亚单元 (CD49d) 的ITGA4基因表达在各种癌症类型中进行了评估.

研究的目的:

评估VLA-4作为固体瘤中RPT的目标.
为了评估[67Cu]Cu-LLP2A的疗效和安全性,这是一个针对VLA-4的化剂,用于临床前成像和RPT.

主要方法:

在公共癌症数据集中分析了ITGA4基因表达.
在22个癌细胞系中通过流细胞计确定VLA-4蛋白表达.
在临床前癌症模型中使用[64Cu]Cu-LLP2A和[67Cu]Cu-LLP2A进行了体内PET/CT成像,生物分布,剂量测量,耐受性和疗效研究.

主要成果:

在各种固体瘤和血液性恶性瘤中,ITGA4的过度表达.
在77%的测试癌细胞系中,VLA-4蛋白表达高.
[64Cu]Cu-LLP2A PET/CT显示了瘤吸收,[67Cu]Cu-LLP2A显示了可接受的毒性特征,主要副作用是胸腺缩,显示了剂量依赖的瘤反应.

结论:

VLA-4在各种癌症组织和细胞系中得到广泛表达,支持其作为RPT点的潜力.
[67Cu]Cu-LLP2A在临床前模型中表现出针对性,对瘤的影响,有利的剂量测量和可接受的毒性概况.
在固体瘤中对RPT进行[67Cu]Cu-LLP2A的进一步研究是有必要的.

更多相关视频

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.